{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:11:03Z","timestamp":1784574663620,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>There is a lack of real-world characterization of healthcare costs and associated cost drivers in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (PH-COPD).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To examine (1) excess healthcare resource utilization (HCRU) and associated costs in patients with PH-COPD compared to COPD patients without PH; and (2) patient characteristics that are associated with higher healthcare costs in patients with PH-COPD.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study analyzed data from the IQVIA PharMetrics<jats:sup>\u00ae<\/jats:sup> Plus database (OCT2014-MAY2020). Patients with PH-COPD were identified by a claims-based algorithm based on PH diagnosis (ICD-10-CM: I27.0, I27.2, I27.20, I27.21, I27.23) after COPD diagnosis. Patients aged \u226540 years and with data available \u226512 months before (baseline) and \u22656 months after (follow-up) the first observed PH diagnosis were included. Patients with other non-asthma chronic pulmonary diseases, PH associated with other causes, cancer, left-sided heart failure (HF), PH before the first observed COPD diagnosis, or right-sided\/unspecified HF during baseline were excluded. Patients in the PH-COPD cohort were matched 1:1 to COPD patients without PH based on propensity scores derived from baseline patient characteristics. Annualized all-cause and COPD\/PH-related (indicated by a primary diagnosis of COPD or PH) HCRU and costs during follow-up were compared between the matched cohorts. Baseline patient characteristics associated with higher total costs were examined in a generalized linear model in the PH-COPD cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2,224 patients with PH-COPD were identified and matched to COPD patients without PH. Patients with PH-COPD had higher all-cause HCRU and annual healthcare costs ($51,435 vs. $18,412, <jats:italic>p<\/jats:italic>&lt;0.001) than matched COPD patients without PH. Among patients with PH-COPD, costs were primarily driven by hospitalizations (57%), while COPD\/PH-related costs accounted for 13% of all-cause costs. Having a higher comorbidity burden and a prior history of COPD exacerbation were major risk factors for higher total all-cause costs among patients with PH-COPD. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment strategies focusing on preventing hospitalizations and managing comorbidities may help reduce the burden of PH-COPD.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02698-9","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:04:54Z","timestamp":1700579094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Tracey","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee M.","family":"Near","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena Rosen","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"issue":"6","key":"2698_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/resp.12772","volume":"21","author":"I Blanco","year":"2016","unstructured":"Blanco I, Piccari L, Barber\u00e0 JA. Pulmonary vasculature in COPD: the silent component. Respirology. 2016;21(6):984\u201394.","journal-title":"Respirology"},{"issue":"1","key":"2698_CR2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.","journal-title":"Eur Respir J"},{"key":"2698_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/COPD.S211841","volume":"15","author":"I Blanco","year":"2020","unstructured":"Blanco I, Tura-Ceide O, Peinado VI, Barber\u00e0 JA. Updated Perspectives on Pulmonary Hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"2698_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/diagnostics11020311","volume":"11","author":"H Olschewski","year":"2021","unstructured":"Olschewski H. The challenge to decide between pulmonary hypertension due to chronic lung disease and PAH with chronic lung disease. Diagnostics. 2021;11(2):311.","journal-title":"Diagnostics"},{"issue":"5","key":"2698_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1183\/09031936.00085612","volume":"41","author":"JM Hilde","year":"2013","unstructured":"Hilde JM, Skj\u00f8rten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J. 2013;41(5):1031.","journal-title":"Eur Respir J"},{"issue":"1","key":"2698_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the european respiratory society (ERS): endorsed by: Association for European Paediatric and congenital cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"issue":"38","key":"2698_CR7","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the european respiratory society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the european Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"12","key":"2698_CR8","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.rmed.2010.05.009","volume":"104","author":"MJ Cuttica","year":"2010","unstructured":"Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104(12):1877\u201382.","journal-title":"Respir Med"},{"issue":"5","key":"2698_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/15412555.2017.1336209","volume":"14","author":"SK Medrek","year":"2017","unstructured":"Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. Admission for COPD Exacerbation is Associated with the clinical diagnosis of pulmonary hypertension: results from a Retrospective Longitudinal Study of a veteran Population. Copd. 2017;14(5):484\u20139.","journal-title":"Copd"},{"issue":"3","key":"2698_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccl.2016.04.003","volume":"34","author":"JR Klinger","year":"2016","unstructured":"Klinger JR. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and treatments. Cardiol Clin. 2016;34(3):413\u201333.","journal-title":"Cardiol Clin"},{"issue":"4","key":"2698_CR11","doi-asserted-by":"publisher","first-page":"204589402110468","DOI":"10.1177\/20458940211046838","volume":"11","author":"RF Munshi","year":"2021","unstructured":"Munshi RF, Pellegrini JR Jr., Patel P, et al. Impact of pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on healthcare utilization. Pulm Circ. 2021;11(4):20458940211046838.","journal-title":"Pulm Circ"},{"key":"2698_CR12","unstructured":"US Bureau of Labor Services. CPI for All Urban Consumers (CPI-U). https:\/\/data.bls.gov\/cgi-bin\/surveymost. Published 2022. Accessed March 29, 2022."},{"issue":"6","key":"2698_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2698_CR14","first-page":"205","volume":"25","author":"AE Wallace","year":"2019","unstructured":"Wallace AE, Kaila S, Bayer V, et al. Health Care Resource utilization and exacerbation rates in patients with COPD stratified by Disease Severity in a commercially insured Population. J Manag Care Spec Pharm. 2019;25(2):205\u201317.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2698_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to Propensity score methods for reducing the Effects of confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"1","key":"2698_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12890-017-0399-1","volume":"17","author":"GA Heresi","year":"2017","unstructured":"Heresi GA, Platt DM, Wang W, et al. Healthcare burden of pulmonary hypertension owing to lung disease and\/or hypoxia. BMC Pulm Med. 2017;17(1):58.","journal-title":"BMC Pulm Med"},{"key":"2698_CR17","doi-asserted-by":"crossref","unstructured":"Cheron C, McBride SA, Antigny F, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev. 2021;30(162):200330.","DOI":"10.1183\/16000617.0330-2020"},{"issue":"6","key":"2698_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/thx.2009.122002","volume":"65","author":"I-C S\u00f8rheim","year":"2010","unstructured":"S\u00f8rheim I-C, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax. 2010;65(6):480.","journal-title":"Thorax"},{"issue":"1","key":"2698_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1378\/chest.11-3241","volume":"144","author":"AD Poms","year":"2013","unstructured":"Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(1):169\u201376.","journal-title":"Chest"},{"issue":"116","key":"2698_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1183\/09059180.00002610","volume":"19","author":"A Anzueto","year":"2010","unstructured":"Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113\u20138.","journal-title":"Eur Respir Rev"},{"issue":"5","key":"2698_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1183\/09031936.03.00115402","volume":"21","author":"JA Barber\u00e0","year":"2003","unstructured":"Barber\u00e0 JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):892.","journal-title":"Eur Respir J"},{"issue":"1","key":"2698_CR22","doi-asserted-by":"publisher","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","volume":"53","author":"SD Nathan","year":"2019","unstructured":"Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914.","journal-title":"Eur Respir J"},{"issue":"8","key":"2698_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1164\/rccm.201801-0095PP","volume":"198","author":"G Kovacs","year":"2018","unstructured":"Kovacs G, Agusti A, Barber\u00e0 JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit Care Med. 2018;198(8):1000\u201311.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02698-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:04:11Z","timestamp":1700618651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02698-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02698-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were accessed in compliance with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). All databases used are de-identified and fall under the US Department of Health and Human Services Policy for the Protection of Human Subjects, and therefore informed consent and Institutional Review Board approval were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Weiss and Ramey are employees of Merck & Co., Inc. Near and Zhao are employees of IQVIA, Inc., which received consulting fees for conducting this study. Xie and Banerji were employees of IQVIA at the time of study conduct. Nathan has received consulting fees and serves on the advisory board for Merck &Co., Inc., United Therapeutics Corporation, Bellerophon Therapeutics, Third Pole Therapeutics and F. Hoffmann-La Roche AG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"455"}}